Showing results (601-610 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|October 3, 2020
Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in CameroonAlexandra Calmy, Tamara Tovar Sanchez, Charles Kouanfack, et al.
The Lancet. HIV|July 31, 2021
Temporal change in population-level prevalence of detectable HIV viraemia and its association with HIV incidence in key populations in India: a serial cross-sectional studyEshan U Patel, Sunil S Solomon, Gregory M Lucas, et al.
The Lancet. HIV|June 6, 2022
Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regressionSamira Hosseini-Hooshyar, Behzad Hajarizadeh, Sahar Bajis, et al.
The Lancet. HIV|June 24, 2022
Integrating HIV and mental health interventions to address a global syndemic among men who have sex with menDon Operario, Shufang Sun, Amiel Nazer Bermudez, et al.
The Lancet. HIV|December 14, 2020
Primary HIV-1 infection in users of pre-exposure prophylaxisJuan Ambrosioni, Elisa Petit, Geoffroy Liegeon, et al.
The Lancet. HIV|February 5, 2022
Use of integrase inhibitors in HIV-associated tuberculosis in high-burden settings: implementation challenges and research gapsAnushka Naidoo, Kogieleum Naidoo, Nesri Padayatchi, et al.
The Lancet. HIV|January 29, 2022
Where are the pregnant and breastfeeding women in new pre-exposure prophylaxis trials? The imperative to overcome the evidence gapDvora L Joseph Davey, Linda-Gail Bekker, Elizabeth A Bukusi, et al.
The Lancet. HIV|July 22, 2022
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trialAnna Turkova, Hylke Waalewijn, Man K Chan, et al.
The Lancet. HIV|March 26, 2022
Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysisAshar Dhana, Yohhei Hamada, Andre P Kengne, et al.
The Lancet. HIV|March 26, 2022
Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort studyLucas C Netto, Karim Y Ibrahim, Camila M Picone, et al.
Pageof 79